Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RENEO PHARMACEUTICALS, INC.

(RPHM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
7.65(c) 7.76(c) 7.98(c) 8.1(c) 7.84 Last
60 703 20 088 67 227 46 949 4 209 Volume
-9.89% +1.44% +2.84% +1.50% -3.21% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -40,1 M - -
Net cash position 2021 146 M - -
P/E ratio 2021 -2,52x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -70,6 M - -
Net cash position 2022 81,8 M - -
P/E ratio 2022 -2,69x
Yield 2022 -
Capitalization 198 M 198 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 23
Free-Float 97,3%
More Financials
Company
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The Company is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd)... 
More about the company
All news about RENEO PHARMACEUTICALS, INC.
09/09RENEO PHARMACEUTICALS : to Participate in Upcoming Investor Conferences
AQ
08/27SECTOR UPDATE : Health Care Stock Fading Near Friday Close
MT
08/27RENEO PHARMACEUTICALS : Shares Jump After CEO, CFO Disclose Purchases
MT
08/27SECTOR UPDATE : Health Care Stocks Rising Friday But Lagging Broader Markets
MT
08/11RENEO PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
08/11RENEO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
08/11RENEO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/11RENEO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
08/11RENEO PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results
AQ
08/11Reneo Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the S..
CI
07/28RENEO PHARMACEUTICALS : Announces First Patient Dosed in the STRIDE Study
AQ
07/28Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
CI
07/09RENEO PHARMACEUTICALS : Says Retiring Officer Cleared to Sell Stock in Lock-Up Waiver
MT
07/09RENEO PHARMACEUTICALS : Announces Partial Waiver of Lock-Up Restriction
AQ
07/07Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference
GL
More news
News in other languages on RENEO PHARMACEUTICALS, INC.

- No features available -

More news
Analyst Recommendations on RENEO PHARMACEUTICALS, INC.
More recommendations
Chart RENEO PHARMACEUTICALS, INC.
Duration : Period :
Reneo Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RENEO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 8,10 $
Average target price 31,33 $
Spread / Average Target 287%
EPS Revisions
Managers and Directors
Gregory J. Flesher President, Chief Executive Officer & Director
Vineet R. Jindal Chief Financial Officer
Michael G. Grey Executive Chairman
Alejandro Dorenbaum Chief Medical Officer
Michael Cruse Senior Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
RENEO PHARMACEUTICALS, INC.0.00%198
MODERNA, INC.305.22%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.41.30%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-9.18%28 939